A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is ...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results.

Incumbent U.S. Reps. Dave Joyce and Michael Rulli, the two Republicans who represent the Mahoning Valley, have significant ...

Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and ...

The gut microbiome’s neuroactive potential is linked to cognition and depression in Chilean older adults, per analysis of 153 Chilean older adults with cognition concerns ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.

Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, ...

Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant ...